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Aim: The aim of the present study was to explore knowledge and attitude of primary care doctors
towards management of postmenopausal symptoms.
Methods: This study is a cross-sectional survey that was conducted from October to December 2010
in the ﬁve health regions in Kuwait. Two centers were selected randomly from each health region. All
physicians who were currently working in the selected centers were asked to participate in the study.
Out of 209 physicians, 142 agreed to participate and completed a self-administered questionnaire.artment of Medical Statistics,
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168 A.A. Al-Eassa et al.Results: The study revealed that 82.4% of physicians hadmoderate knowledge about treatment options
for postmenopausal symptoms, 88.0% discussed postmenopausal symptoms with their patients, and
45.1% of them either described or referred their patients for hormonal replacement therapy (HRT). The
correct answers regarding 10 statements related to theWomenHealth Initiative ﬁndingwere ranging from
2.8% to 78.9%which indicated low level of knowledge. Regarding the effectiveness of hormonal replace-
ment therapy in postmenopausalwomen, themajority of the physicians agreed correctly thatHRT is effec-
tive in prevention of osteoporosis (87.3%), treatment of vasomotor symptoms (83.7%), and treatment of
vulvo-vaginal symptoms (82.4%). Therewas a variation amongphysicians opinion about the effectiveness
of certain treatment options for managing hot ﬂushes in postmenopausal women.
Conclusion: The results suggest that there is a lack of primary care physicians knowledge and conﬁdence in
recognizing signs and symptoms ofmenopause and in identifying andprescribing appropriate management.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Menopause is a physiological event occurring with ovarian
failure and marks the end of women’s reproductive life.1 The
average age of menopause is 51 years.1 In 1960, the world
population of women aged over 60 was below 250 million,
but it is estimated that in the year 2030,1,2 billion will be peri
or postmenopausal and that this total will increase by 4.7 mil-
lion a year.2 The average woman in the developed world can
now expect to spend approximately one-third of her life in
postmenopausal state.3
Because of these predicted changes in population structure,
physicians are beginning to see that menopause is not a negligi-
ble phenomenon but a major public health problem.2 Attitudes,
perceptions, and expectations are part of the psychosocial phe-
nomenon surrounding menopause.4 Women in midlife and
health professionals believe that attitude plays a role in the
experience of menopause.5
Hormonal changes at menopause are associated with
numerous physical and psychological symptoms like vasomotor
symptoms, sleep disturbances, mood alteration, depression,
urinary tract infection, vaginal atrophy, and increased health
risks for several chronic disorders including osteoporosis, car-
diovascular disease, and loss of cognitive function. Menopausal
symptoms are found to be less common in societies where men-
opause is viewed as a positive rather than negative event.4
The Massachusetts women health study did a longitudinal
study on more than 2000 women between 45 and 55 years. This
study showed that negative attitude towardsmenopause leads to
less favorable mode of climacteric.6 This cultural aspect of
menopausal symptomshasbeen discussed in anumber of studies
among Asian women including Japanese and Chinese popula-
tion.1 It is well established that hormonal replacement therapy
(HRT) is an effective means of treating postmenopausal symp-
toms and preventing long term complications, such as osteopo-
rosis.7–10 The HRT usage rate is low largely because majority
remain poorly informed about this therapy.11,12
Therefore, doctor’s knowledge and perception towards men-
opause and participation in health related activities is expected
to be more in primary health care (PHC) centers. The present
study was an approach to evaluate primary care physician’s
knowledge and attitude towards management of postmeno-
pausal symptoms in primary health care centers in Kuwait.2. Methods
2.1. Setting and design
The health care system in Kuwait is divided into ﬁve regional
health authorities. PHC is provided by 82 centers served by
either family practice physicians (FPs) or general practitioners
(GPs). This study is a cross-sectional survey that was con-
ducted from October to December 2010 in the ﬁve health
regions. The sampling unit used in this survey was the health
center. Ten centers were randomly selected from the ofﬁcial
national list of all PHC (two from each health region). All
PHC physicians who were currently working in the selected
centers were asked to participate in the study. Out of 209 phy-
sicians, 142 physicians agreed to participate in the study and
returned the ﬁlled self-administered questionnaires. Participa-
tion was optional and verbal consent was obtained prior to
conducting the survey. All the necessary approvals for carrying
out the research were obtained. The Ethical Committee of the
Kuwaiti Ministry of Health approved the research.
2.2. Study questionnaires
The predesigned self-administered questionnaire derived from
other published studies dealing with the same topic as well
as from our own experience was used to collect the informa-
tion from the physicians. The administrative time for ﬁlling
it was 20–30 min. In order to maintain conﬁdentiality, ques-
tionnaire was made anonymous. It consisted of two parts.
The ﬁrst part includes personal and working characteristics
(age, gender, nationality, marital status, and years at work,
specialty, education certiﬁcates and jobs). The second part
included questions about knowledge and attitude of physicians
towards menopause (having enough knowledge about treat-
ment option for postmenopausal symptoms, discussion of
postmenopausal symptoms with patients, prescription or refer-
ral of patient for HRT, absolute and relative contra indication
for HRT in menopause).
2.3. Statistical analysis
The Statistical Package for Social Sciences (SPSS-17) was used
for data processing. Simple descriptive statistics were used
Table 1 General characteristics of participating physicians
and their work features.
Characteristics No. %
Age (year)
<35 26 18.3
35 52 36.6
45 48 33.8
P55 16 11.3
Gender
Males 86 60.6
Females 56 39.4
Nationality
K 26 18.3
NK 116 81.7
Education
Bach 53 37.3
master 63 44.4
PHD or board 26 18.3
Marital status
Single 16 11.3
Married 122 85.9
Divorced 4 2.8
Experience (year)
<5 13 9.2
5–10 31 21.8
>10 98 69.0
Specialty
GP 111 78.2
FP 31 21.8
Total 142 100.0
Table 2 Physicians knowledge and attitude towards postmen-
opausal management.
Variable No. %
Knowledge about treatment option for postmenopausal symptoms
I have no knowledge 9 6.3
I have moderate knowledge 117 82.4
I have good knowledge 16 11.3
Discussion of postmenopausal symptoms with your patients
No 17 12.0
Yes 125 88.0
Prescription or referral of any patient for hormonal replacement
therapy
No 78 54.9
Yes 64 45.1
Symptoms for which physician referred patients for or prescribed
HRT
Treatment of vasomotor symptoms 32 50.0
Prevention of cardiovascular disease 5 7.8
Prevention or treatment of osteoporosis 24 37.5
Treatment of cognitive symptoms 3 4.7
Subtotal 64a 100.0
Total 142 100.0
a The question was not applicable among 78 physicians
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3. Results
Out of 219 distributed questionnaires, 142 were returned back
with 64.8% response rate. Table 1 describes the general char-
acteristics of participating physicians. Their mean age ranged
from 25 to 66 years was a mean of 43.3 ± 9.1 years, more than
80% of them were above 35 year of age. Males were predom-
inating females (60.6% versus 39.4%). Most of physicians
(81.7%) were non-Kuwaiti and 69.0% of them had 10 or more
years of experience as PHC physicians. According to specialty,
78.2% were GPs and 21.8% were FPs. Nearly about two-third
of the participating physicians have master, PhD or Board cer-
tiﬁcates (62.7%).
Table 2 reveals that 6.3% of participating physicians said
that they had poor knowledge about treatment options for
postmenopausal symptoms and 82.4% declared that they
had moderate knowledge. The majority of them (88.0%) stated
that they have ever discussed postmenopausal symptoms with
their patients. Among them, only 45.1% described or referred
their patients for HRT.
Among those physicians who prescribed or referred pa-
tients for HRT, 50.0% did these for treatment of vasomotor
symptoms, 37.5% attributed that for prevention or treatment
of osteoporosis, while the minority did this for prevention ofcardiovascular disease or treatment of cognitive symptoms
(7.8% and 4.7%, respectively)
Table 3 Illustrate the correct answers regarding 10 statements
related to theWomenHealth Initiative ﬁnding.When the physi-
cian asked about the effect of prescribing estrogen plus proges-
tin, only 12.7% answered correctly increased heart attack
frommultiple chooses. Only 2.8% chose correctly the increased
risk of heart attack as a result of prescribing estrogen alone.
According to FDA recommendations on hormonal therapy,
36.6% choose approved estrogen therapy for relief of moderate
to severe hot ﬂashes as correct choice. However, 31.0% of the
physicians chose patients on combine HRT have increased risk
of breast cancer after average 2–5 years correctly. Only 12.0%
of the physicians chose correctly that FDA did not approved
lower dose single tablet of prempro, containing 0.45 estrogen
and 1.5 progestin for prevention of coronary heart disease or
other cardiovascular disease. Severe liver disease, history of
uterine ﬁbrosis and venous thrombosis were chosen correctly
as absolute contra indication for HRT in menopause by
78.9% of the physicians. On the other hand, only 21.8% chose
correctly undiagnosed vaginal bleeding as relative contraindica-
tion for HRT in menopause. Regarding side effects, only 3.5%
chose correctly severe abdominal pain as common side effect
to HRT and 35.9% chose correctly severe depression as uncom-
mon side effect to HRT.Moreover, 29.6% chose sexual desire is
decreased after the menopause as correct answer.
Regarding physicians opinion about the effectiveness of
HRT in postmenopausal women, the majority of the physicians
agreed correctly that HRT is effective in prevention of osteopo-
rosis (87.3%), treatment of vasomotor symptoms (hot ﬂashes)
(83.7%) and treatment of vulvo-vaginal symptoms (82.4%).
On the other hand, around one-third of the physicians correctly
disagreed that HRT is effective in prevention of chronic heart
disease (28.1%), stroke (35.9%), treatment of dementia or Alz-
heimer (36.6%), skin wrinkles (33.1%), and increasing sexual
Table 3 Proportion of physicians answered correctly certain statements for management of menopausal symptoms.
Women Health Initiative ﬁndings No. %
– Compared with placebo, prescribing estrogen plus progestin resulted in increased heart
attack
18 12.7
– Compared with placebo, prescribing estrogen alone resulted in increased risk of heart
attack
4 2.8
– According to FDA recommendations on hormonal therapy, estrogen therapy (combined or
alone) approved for relief of moderate to severe hot ﬂashes
52 36.6
– Patients on combine hormonal replacement therapy (HRT) have increased risk of breast
cancer after average 2–5 years
44 31.0
– FDA did not approved lower dose single tablet of prempro, containing 0.45 estrogen and
1.5 progestin for prevention of coronary heart disease or other cardiovascular disease
17 12.0
– Absolute contra indication for HRT in menopause is: severe liver disease, history of uterine
ﬁbrosis, venous thrombosis
112 78.9
– Relative contraindication for HRT in menopause is: undiagnosed vaginal bleeding 31 21.8
– Common side eﬀect to HRT is: severe abdominal pain 5 3.5
– Uncommon side eﬀect to HRT is: severe depression 51 35.9
– Which of the following statement is correct? Sexual desire is decreased after the menopause 42 29.6
Total 142 100.0
Table 4 Proportion of physicians with correct opinion
regarding postmenopausal symptoms.
Physician opinion No. %
Hormonal replacement therapy
in postmenopausal women is eﬀective for
Prevention of osteoporosis 124 87.3
Prevention of CHD 40 28.2
Prevention of stroke 51 35.9
Treatment of dementia or Alzheimer 52 36.6
Treatment of skin wrinkles 47 33.1
Increasing sexual drive 31 21.8
Treatment of vasomotor symptoms (hot ﬂashes) 119 83.8
Treatment of vulvo-vaginal symptoms 117 82.4
Eﬀective managing for hot ﬂashes
in postmenopausal women
SSRI and venlafaxine (Eﬀexor) 44 31.0
Clonidine (Catapres) 18 12.7
Soy isoﬂavones 13 9.2
Red clover 12 8.5
Black cohosh 14 9.9
Belladonna/ergotamine tatrate/phenobarbital
combination
17 12.0
Dong quai 11 7.7
Evening primrose oil 7 4.9
Gabapentin (neurontin) 29 20.4
Ginseng 22 15.5
Mirtarzapine (Desyrel) 16 11.3
Vitamin E 28 19.7
Wild yam 16 11.3
Behavioral/life style modiﬁcation 78 54.9
Others 5 3.5
Total 142 100.0
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tiveness of certain treatment options for managing hot ﬂashes
in postmenopausal women, SSRI and venlafaxine (Effexor),
belladonna/ergotamine tatrate/phenobarbital combination,
gabapentin (neurontin), and behavioral/life style modiﬁcation
were chosen correctly as effective options by 31.0%, 12.0%,
20.4%, and 54.9%, respectively by the physicians. On the other
hand, clonidine (Catapres), soy isoﬂavones, red clover, blackcohosh, dong quai, evening primrose oil, ginseng, mirtarzapine
(Desyrel), vitamin E, and wild yam were chosen correctly by
lower proportions of physicians as not effective options for
managing hot ﬂashes in postmenopausal women as shown in
Table 4.
4. Discussion
Menopause induces a lot of disturbances in the body that the
woman is most often not aware of.13 Post-menopause is the
stage in a woman’s life that follows menopause. It is generally
believed that the post-menopausal phase begins when 12 full
months have passed since the last menstrual period.1 It is
accompanied by decreases of certain hormone production
leading to a group of symptoms, bone loss, and the risk of
heart disease. Although practice guidelines on HRT have been
developed and several physician surveys and review articles
have been published on the topic, there are few clear cut rec-
ommendations on when to prescribe HRT, which pretreatment
investigations to conduct, which regimens to prescribe, how
long HRT should be prescribed or what schedule of surveil-
lance should be followed.14–21 In agreement with that, 82.4%
of PHC physicians participating in this study declared that
they had moderate knowledge about treatment options for
postmenopausal symptoms. Moreover, although 88.0% of
the physicians discussed postmenopausal symptoms with their
patients, only about half of them either described or referred
their patients for HRT. Our ﬁndings indicate that 50.0% of
the physicians did these for treatment of vasomotor symptoms,
37.5% attributed that for prevention or treatment of osteopo-
rosis, while the minority did this for prevention of CVD or
treatment of cognitive symptoms (7.8% and 4.7%, respec-
tively). These ﬁnding indicated that the vast majority of physi-
cians are not familiar with the beneﬁts of HRT described in the
medical literature and practice guidelines (protection against
osteoporosis, fractures and CAD) and risks from long-term
use (endometrial and breast cancer).
Most agreement in the literature appears to be about the
beneﬁts of estrogen in preventing osteoporosis and frac-
tures.4–16 There is some question about the beneﬁts in prevent-
ing coronary artery disease (CAD). Observational studies
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about 30%–50% the risk among women not using estro-
gen.17,18 However, in a subsequent randomized controlled clin-
ical trial involving women with CAD, the rate of CAD events
was not reduced.19
The majority of the respondents considered the prevention
of osteoporosis and the presence of risk factors for osteoporo-
sis as important or very important reasons for prescribing
HRT. The results of the Women’s Health Initiative (WHI)
study of hormone therapy in post-menopausal women, pub-
lished in 2002, have prompted many women and primary care
physicians to reconsider the use of estrogen and progesterone
hormone therapy to alleviate hot ﬂashes.20 In that study,
16,608 healthy, post-menopausal women with an intact uterus
were randomized to receive therapy with conjugated equine
estrogens plus medroxyprogesterone acetate, or placebo.20
The results of the current study about the correct answers
regarding 10 statements related to the Women Health Initia-
tive ﬁnding revealed lower level of knowledge for all items ex-
cept for the item related to absolute contra indication for HRT
in menopause where, more than three quarters of physicians
(78.9%) answered correctly severe liver disease, history of uter-
ine ﬁbrosis, venous thrombosis.
Doctors were not conﬁdent prescribing this type of therapy
and considered it a specialized form of treatment that requires
investigations.13 Thus, most of the physicians surveyed were
consistent with the epidemiological literature18 and practice
guidelines,15,16,21 which recommend combined HRT for women
who have an intact uterus and are at risk of endometrial cancer.
Although observational studies have consistently shown that
estrogen protects against CAD,17,18 a recent randomized,
blinded, placebo-controlled trial involving menopausal women
with CAD found that a combined estrogen–progestin regimen
did not reduce the overall rate of CAD events.19 Although that
trial assessed HRT as secondary prevention, its ﬁndings will
probably result in a re-evaluation of the role of estrogen in the
prevention of heart disease.22 Similarly, the majority of the par-
ticipating physicians agreed correctly that HRT is effective in
prevention of osteoporosis (87.3%), treatment of vasomotor
symptoms (hot ﬂashes) and treatment of vulvo-vaginal symp-
toms. On the other hand, a round one-third of the physicians
correctly disagreed that HRT is effective in prevention of
CHD, stroke, treatment of dementia or Alzheimer, skin
wrinkles, and increasing sexual drive.
Regarding physicians’ opinion about the effectiveness of
certain treatment options for managing hot ﬂashes in postmen-
opausal women, one-third of physicians in the present study
agreed that SSRIs and venlafaxine (Effexor), a serotonin and
norepinephrine reuptake inhibitor, as effective options for
managing hot ﬂashes in post-menopausal women. Other stud-
ies have shown an absolute risk reduction (ARR) in hot ﬂashes
of 19–60% with these agents compared with placebo.23,24
Clonidine (Catapres) has been found to reduce hot ﬂashes
by 12.7%. Similarly other studies reported a decrease by 15–
20% (ARR) compared with placebo.25,26 Another study, in
which clonidine was administered transdermally in 30 post-
menopausal women, showed that clonidine decreased the num-
ber and the severity and duration of hot ﬂashes compared with
placebo.26
PHC physicians have evaluated the effectiveness of soy
isoﬂavones as tablets, capsules, and liquids in management of
hot ﬂashes in lower proportion (9.2%). A small pilot study ofthe effects of soy isoﬂavones in 39 menopausal women reported
a 20% ARR in hot ﬂashes weekly compared with placebo.27
Other studies have shown no difference in effectiveness between
isoﬂavones and placebo.28,29
The American College of Obstetricians and Gynecologists
(ACOG) states that soy and isoﬂavones may be helpful in the
short-term treatment of vasomotor symptoms. However, given
the possibility of their interacting with estrogen, these agents
should not be considered free of potential harm for women, par-
ticularly those who have an estrogen-dependent cancer.30
Only 8.5% of the physicians reported the effectiveness red
clover, like soy, contains isoﬂavones, which act as agonist/
antagonists on estrogenic receptors. In two small pilot studies,
31,32 researchers compared red clover with placebo in post-
menopausal women and found no difference in effectiveness
of reducing hot ﬂashes. In a randomized study with 252 men-
opausal women, researchers compared two different commer-
cial red clover products with placebo. All groups reported
signiﬁcant declines in hot ﬂashes compared with baseline, but
neither of the red clover products demonstrated superiority
over placebo.33
Black cohosh shows promise for treatment of hot ﬂashes, but
study results are inconsistent.34–36Black cohosh is themost stud-
ied and perhaps the most popular herb for treatment of hot
ﬂashes. Typically, it is not used on a long-term basis. However,
in the current study, black cohosh was reported as an effective
management by 9.9%of the physician.A study inwhich 97men-
opausal women were randomized to estrogen, black cohosh, or
placebo showed black cohosh to be as effective as estrogen and
superior to placebo in decreasing hot ﬂash symptoms.34 ACOG
states that black cohosh may be helpful in the short-term treat-
ment of women with vasomotor symptoms.30
In consistent with other studies, other agents also have been
used for the treatment of hot ﬂash symptoms in menopause,
including belladonna/ergotamine tartrate/phenobarbital
combination, dong quai, evening primrose oil, gabapentin
(neurontin), ginseng, mirtazapine (Remeron), trazodone
(Desyrel), vitamin E, and wild yam, but there are few
published data on their effectiveness. Belladonna/ergotamine
tartrate/phenobarbital combination and gabapentin were more
effective than placebo in reducing hot ﬂashes in two small clin-
ical trials. However, larger clinical studies are needed to sup-
port these initial ﬁndings.37–45
5. Conclusion
The study revealed a general lack of knowledge about meno-
pause and HRT. Better education about menopause and its
management for healthcare providers in PHC is needed regard-
ing the long-term risks associated with menopause and the role
of HRT so that physician can take health decisions, which may
results in improvement in quality of life of these women.References
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